QQQ   444.84 (+0.00%)
AAPL   170.76 (-1.47%)
MSFT   420.78 (-0.15%)
META   488.94 (-1.00%)
GOOGL   150.75 (-0.08%)
AMZN   180.84 (+0.56%)
TSLA   176.62 (-1.79%)
NVDA   907.43 (+0.55%)
NIO   4.63 (-0.86%)
AMD   181.86 (+1.26%)
BABA   72.56 (+1.35%)
T   17.56 (+0.06%)
F   13.27 (+1.61%)
MU   118.43 (-0.60%)
CGC   9.78 (+2.41%)
GE   175.57 (-2.53%)
DIS   122.69 (+1.41%)
AMC   3.74 (-13.82%)
PFE   27.88 (+0.36%)
PYPL   66.85 (+0.42%)
XOM   115.51 (+0.47%)
QQQ   444.84 (+0.00%)
AAPL   170.76 (-1.47%)
MSFT   420.78 (-0.15%)
META   488.94 (-1.00%)
GOOGL   150.75 (-0.08%)
AMZN   180.84 (+0.56%)
TSLA   176.62 (-1.79%)
NVDA   907.43 (+0.55%)
NIO   4.63 (-0.86%)
AMD   181.86 (+1.26%)
BABA   72.56 (+1.35%)
T   17.56 (+0.06%)
F   13.27 (+1.61%)
MU   118.43 (-0.60%)
CGC   9.78 (+2.41%)
GE   175.57 (-2.53%)
DIS   122.69 (+1.41%)
AMC   3.74 (-13.82%)
PFE   27.88 (+0.36%)
PYPL   66.85 (+0.42%)
XOM   115.51 (+0.47%)
QQQ   444.84 (+0.00%)
AAPL   170.76 (-1.47%)
MSFT   420.78 (-0.15%)
META   488.94 (-1.00%)
GOOGL   150.75 (-0.08%)
AMZN   180.84 (+0.56%)
TSLA   176.62 (-1.79%)
NVDA   907.43 (+0.55%)
NIO   4.63 (-0.86%)
AMD   181.86 (+1.26%)
BABA   72.56 (+1.35%)
T   17.56 (+0.06%)
F   13.27 (+1.61%)
MU   118.43 (-0.60%)
CGC   9.78 (+2.41%)
GE   175.57 (-2.53%)
DIS   122.69 (+1.41%)
AMC   3.74 (-13.82%)
PFE   27.88 (+0.36%)
PYPL   66.85 (+0.42%)
XOM   115.51 (+0.47%)
QQQ   444.84 (+0.00%)
AAPL   170.76 (-1.47%)
MSFT   420.78 (-0.15%)
META   488.94 (-1.00%)
GOOGL   150.75 (-0.08%)
AMZN   180.84 (+0.56%)
TSLA   176.62 (-1.79%)
NVDA   907.43 (+0.55%)
NIO   4.63 (-0.86%)
AMD   181.86 (+1.26%)
BABA   72.56 (+1.35%)
T   17.56 (+0.06%)
F   13.27 (+1.61%)
MU   118.43 (-0.60%)
CGC   9.78 (+2.41%)
GE   175.57 (-2.53%)
DIS   122.69 (+1.41%)
AMC   3.74 (-13.82%)
PFE   27.88 (+0.36%)
PYPL   66.85 (+0.42%)
XOM   115.51 (+0.47%)
NASDAQ:PRTG

Portage Biotech (PRTG) Stock Price, News & Analysis

$0.58
+0.05 (+8.33%)
(As of 10:59 AM ET)
Today's Range
$0.55
$0.64
50-Day Range
$0.42
$1.07
52-Week Range
$0.34
$4.40
Volume
12,607 shs
Average Volume
64,249 shs
Market Capitalization
$10.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

Portage Biotech MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
1,353.0% Upside
$8.50 Price Target
Short Interest
Healthy
0.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Portage Biotech in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.03) to ($0.65) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.46 out of 5 stars

PRTG stock logo

About Portage Biotech Stock (NASDAQ:PRTG)

Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.

PRTG Stock Price History

PRTG Stock News Headlines

PRTG: Extending the Runway
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
Portage Biotech Inc PRTG
H.C. Wainwright downgrades Portage Biotech on financing overhang
Portage Biotech just downgraded at H.C. Wainwright, here's why
PRTG: Bridging I-O: Working in Harmony with Checkpoints
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Portage Biotech Reports Business and Strategic Update
Portage Biotech GAAP EPS of -$0.29
Analyst Expectations for Portage Biotech's Future
Portage Biotech in Keytruda Collaboration With Merck
Portage Biotech Inc (PRTG) Receives a Buy from H.C. Wainwright
See More Headlines
Receive PRTG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Portage Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Fiscal Year End
3/31/2024
Next Earnings (Estimated)
7/29/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Crude petroleum & natural gas
Sub-Industry
N/A
Current Symbol
NASDAQ:PRTG
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.50
High Stock Price Target
$11.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+1,474.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-104,610,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.45 per share

Miscellaneous

Free Float
N/A
Market Cap
$9.61 million
Optionable
Optionable
Beta
0.96
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Ian B. Walters M.B.A. (Age 55)
    M.D., CEO & Chairman of Board
    Comp: $967.65k
  • Mr. Allan J. Lee Shaw CPA (Age 60)
    Chief Financial Officer
    Comp: $524.08k
  • Mr. Steven Innaimo
    Vice President of Project Management & Operations
  • Dr. Robert A. Kramer Ph.D.
    Chief Scientific Officer
  • Mr. Brian Wiley (Age 56)
    Chief Business Officer
    Comp: $220.69k
  • Mr. Justin Fairchild
    Vice President of Development
  • Mr. Joseph Ciavarella
    Chief Accounting Officer

PRTG Stock Analysis - Frequently Asked Questions

Should I buy or sell Portage Biotech stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Portage Biotech in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PRTG shares.
View PRTG analyst ratings
or view top-rated stocks.

What is Portage Biotech's stock price target for 2024?

2 analysts have issued twelve-month target prices for Portage Biotech's shares. Their PRTG share price targets range from $6.00 to $11.00. On average, they anticipate the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 1,353.0% from the stock's current price.
View analysts price targets for PRTG
or view top-rated stocks among Wall Street analysts.

How have PRTG shares performed in 2024?

Portage Biotech's stock was trading at $1.82 at the start of the year. Since then, PRTG shares have decreased by 67.9% and is now trading at $0.5850.
View the best growth stocks for 2024 here
.

Are investors shorting Portage Biotech?

Portage Biotech saw a drop in short interest in March. As of March 15th, there was short interest totaling 15,400 shares, a drop of 84.6% from the February 29th total of 100,200 shares. Based on an average daily volume of 62,600 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.2% of the shares of the stock are sold short.
View Portage Biotech's Short Interest
.

When is Portage Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, July 29th 2024.
View our PRTG earnings forecast
.

How were Portage Biotech's earnings last quarter?

Portage Biotech Inc. (NASDAQ:PRTG) posted its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.09.

Who are Portage Biotech's major shareholders?

Portage Biotech's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (10.54%), PEAK6 Investments LLC (0.29%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Portage Biotech?

Shares of PRTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRTG) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners